Natukunda, Eva
Szubert, Alexander J.
Bamford, Alasdair
Doerholt, Katja
Gibb, Diana M.
Wandera, Centurio
Nakalyango, Aidah
Griffiths, Anna
Monkiewicz, Lara
Nangiya, Joan J.
Nambi, Esther
Musiime, Victor
Musoke, Phillipa
Funding for this research was provided by:
European and Developing Countries Clinical Trials Partnership (TRIA2015-1078,, TRIA2015-1078,, TRIA2015-1078,, TRIA2015-1078,, TRIA2015-1078,, TRIA2015-1078,, TRIA2015-1078,, TRIA2015-1078,, TRIA2015-1078,, TRIA2015-1078,, TRIA2015-1078,, TRIA2015-1078,)
Article History
Received: 7 December 2023
Accepted: 16 June 2025
First Online: 4 July 2025
Declarations
:
: The CHAPAS 4 trial was approved by Joint Clinical Research Centre Institutional Review Board (Reference number JC 1417) and the sub-study was approved by the Makerere University College of Health Sciences (Reference number 2019 − 135). In addition, the main study and sub study were approved by the Uganda National Council of Science and Technology. (Reference number HS:2369). Furthermore, regulatory approval for CHAPAS 4 was obtained from the National Drug Authority (Reference number CTC 066).Parents or legal guardians provided written informed consent for study participation. In addition, children aged eight years and above provided written informed assent.
: Not applicable.
: The authors declare no competing interests.